Invectys SAS logo

Invectys SAS

Invectys is engaged in the development of a promising new wide range therapeutic cancer vaccines, based on the human telomerase gene technology.

Invectys was founded by Dr. Pierre Langlade Demoyen & Prof. Simon Wain-Hobson, both senior staff members at the Institut Pasteur in Paris and also holds an exclusive worldwide development rights to telomerase vaccination developed at Institut Pasteur.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://www.invectys.com
Founded2010
Disease Focus
Development Stage
STOCK CODENon Listed
Address
Pepiniere Paris Sante Cochin27,rue du Faubourg Saint Jaues,75014
Paris
France
Email
Contact Number
+33 1 81 80 05 20

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/invectys
” connections=”true” suffix=””]

Invectys recombinant lentiviral vector expressing the human telomerase reverse transcriptase (lv-hTERT) vaccination. Unlike conventional hTERT peptide or DNA immunization, a single lv-hTERT vector immunization induces potent and broad HLA-B7-restricted CTL responses against hTERT.

In July 2017, Invectys raises 4.3 Million Euros. Since inception Invectys has raised more than 23 Million Euros from various investors